Agitatie en agressie bij dementie: ontwerp van een evidence-based algoritme voor medicamenteuze behandeling

  • Dr. Peter van Domburg
  • Marion Vromen
  • Janine Collet
  • Monique Durlinger
  • Serge Roufs
  • Jos Schols
  • Walther Sipers
  • Mike Verkaaik
  • Frans Verhey
Article
  • 1.8k Downloads

Samenvatting

Terwijl onderzoek naar de mogelijkheden van ziektemodulerende medicatie bij dementie een boeiende ontwikkeling doormaakt, is de aandacht in de huidige klinische praktijk toch nog vooral gericht op symptoombestrijding. De behandeling van probleemgedrag speelt daarin een hoofdrol. De wetenschappelijke, evidence based (EBM), literatuur over analyse en behandeling van probleemgedrag is echter beperkt en het ontbreekt dan ook aan breder inzetbare richtlijnen.

Om hierin verandering te brengen werd door een werkgroep van ervaren specialisten uit verschillende disciplines een eerste praktisch bruikbare leidraad ontworpen op basis van beschikbare EBM-gegevens, voor medicamenteuze behandeling van agitatie en agressie bij dementie. Uitgangspunt daarbij is dat agitatie en agressie uitingen zijn van distress (uitgedrukt in het concept BPSD: ‘behavioral and psychological symptoms in dementia’) en een daarop gerichte analyse vereisen. Pas als niet-medicamenteuze maatregelen ter vermijding van distress falen kan in acute of niet-acute situaties medicamenteuze behandeling gewenst zijn. Er zijn maar weinig middelen die daarbij de toets der kritiek kunnen doorstaan en/of breed toepasbaar zijn. Vervolgens vereist de toepassing van medicatie een nauwgezette monitoring van het effect. De doelstelling van ons algoritme is vooral ook gestructureerde ervaring op te doen met medicamenteuze behandeling van agitatie en agressie bij dementie en verder wetenschappelijk onderzoek naar analyse en behandeling van BPSD te stimuleren.

Literatuur

  1. 1.
    Ackerknecht EH. Voorwoord. In: Esquirol JED. Geestesziekten. Uitgeverij Candide, Amsterdam 1993.Google Scholar
  2. 2.
    Aalten P, et al. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium. Part I. Dementia and Geriatric Cognitive Disorders. 2007;24:457–463.CrossRefGoogle Scholar
  3. 3.
    Gauthier S, et al. Management of behavioural problems in Alzheimer’s disease. Int Psychogeriatrics 2010;22(3):346–372.CrossRefGoogle Scholar
  4. 4.
    Olde Rikkert MGM, Lemstra EW, Verhey FRJ. Te kleine rol voor tweede lijn in NHG-standaard ‘Dementie’. Ned T Geneeskunde 2012;156:A5554.Google Scholar
  5. 5.
    KNMG. Antipsychotica bij probleemgedrag bij dementia in verpleeg- en verzorgingshuis. GeBu 2013;47:27–33.Google Scholar
  6. 6.
    Kat M. The neuropsychiatry of dementia. Psychometrics, clinical implications and outcome. Thesis. Amsterdam 2009.Google Scholar
  7. 7.
    Cohen-Mansfield J, Libin A, Marx MS. Non-pharmacological treatment of agitation: a controlled trial of systematic individualized intervention. J Gerontol 2007;62A(8):908–916.CrossRefGoogle Scholar
  8. 8.
    Ballard CG, et al. Management of agitation and aggression associated with Alzheimer disease. Nature Reviews Neurology 2009;5:245–255.PubMedCrossRefGoogle Scholar
  9. 9.
    Verenso (NVVA). Richtlijn probleemgedrag. Beroepsvereniging van verpleeghuisartsen en sociaal geriaters. 2008.Google Scholar
  10. 10.
    Engelborghs S, et al. Neuropsychiatric symptoms of dementia: cross-sectional analysis from a prospective, longitudinal Belgian study. Int J Geriat Psychiatry 2005;20:1028–1037.CrossRefGoogle Scholar
  11. 11.
    Schreinzer D, et al. Components of behavioural pathology in dementia. Int J Geriat Psychiatry 2005;20:137–145.CrossRefGoogle Scholar
  12. 12.
    Aalten P, et al. Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord 2008;25:1–8.CrossRefGoogle Scholar
  13. 13.
    Savva GM, et al. 2009. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Brit J Psychiat 194:212–219.PubMedCrossRefGoogle Scholar
  14. 14.
    Maurer K, Volk S, Gerbaldo H. Auguste D and Alzheimer’s disease. The Lancet 1997;349:1546–1549.CrossRefGoogle Scholar
  15. 15.
    Van der Mussele S, et al. Behavioral symptoms in mild cognitive impairment as compared with Alzheimer’s disease and healthy older adults. Int J Geriatr Psychiatry 2013;28:265–275.PubMedCrossRefGoogle Scholar
  16. 16.
    Cummings JL. The neuropsychiatry of Alzheimer’s disease and relate dementias. London 2003. Martin Dunitz.CrossRefGoogle Scholar
  17. 17.
    Rosen HJ, Allison SC, Schauer GF, Gorno-Tempini ML, Weiner MW, Miller BL. Neuroanatomical correlates of behavioural disorders in dementia. Brain 2005;128:2612–2625.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Kaye ED, et al. Frontotemporal Dementia and Pharmacologic Interventions. The J Neuropsychiat Clin Neurosci 2010;22:19–29.CrossRefGoogle Scholar
  19. 19.
    Zuidema SU, de Jonghe JFM, Verhey FRJ, Koopmans RTCM. Environmental correlates of neuropsychiatric symptoms in Dutch nursing home patients with dementia. Int J Geriatr Psychiatry 2010;25:14–22.PubMedGoogle Scholar
  20. 20.
    Zuidema SU, de Jonghe JFM, Verhey FRJ, Koopmans RTC. Psychotropic drug prescription in nursing home patients with dementia: influence of environmental correlates and staff distress on physicians’ prescription behaviour. Int Psychogeriatrics 2011;23(10):1632–1639.CrossRefGoogle Scholar
  21. 21.
    Ballenger JF. Self, senility, and Alzheimer’s disease in modern America. A History. John Hopkins University Press, Baltimore 2006.Google Scholar
  22. 22.
    Zuidema SU. Neuropsychiatric symptoms in Dutch nursing home patients with dementia. Thesis. Nijmegen 2007.Google Scholar
  23. 23.
    Cohen-Mansfield J, Libin A. Assessment of agitation in elderly patients with dementia: correlations between informant rating and direct observation. In J Geriatr Psychiat 2004;19:881–891.CrossRefGoogle Scholar
  24. 24.
    Reisberg B, Borenstein J, Salob S, Ferris SH, Franssen E. Behavioural symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry 1987;48:9–15.PubMedGoogle Scholar
  25. 25.
    Cummings JL, et al. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2380–2314.Google Scholar
  26. 26.
    De Jonghe JFM, Kat MG, Kalisvaart CJ, Boelaarts L. Neuropsychiatric inventory questionnaire (NPIQ): A validity study of the Dutch form. T Gerontol Geriatr 2003;34(2):74–77.Google Scholar
  27. 27.
    De Jonghe JFM. Factor structure and validity of the Dutch version of the Cohen-Mansfield Agitation Inventory (CMAI-D). J Am Geriatr Soc 1996;44(7):888–889.PubMedGoogle Scholar
  28. 28.
    Cohen-Mansfield, J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry 2001;9:361–381.PubMedGoogle Scholar
  29. 29.
    Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005;162:1996–2021.PubMedCrossRefGoogle Scholar
  30. 30.
    O’Connor DW, Ames D, Gardner B, King M. Psychological treatments of psychological symptoms in dementia: a systematic review of reports meeting quality standards. Int Psychogeriatrics 2009;21(2):241–251.CrossRefGoogle Scholar
  31. 31.
    Zuidema SU. Probleemgedrag bij ouderen met dementie. T Ouderengeneeskunde 2010;5:187–193.Google Scholar
  32. 32.
    Hensiek AE, Trimble MR. Relevance of new psychotropic drugs for the neurologist. J Neurol Neurosurg Psychiatry 2002;72:281–285.PubMedCrossRefGoogle Scholar
  33. 33.
    Rochon PA, et al. Antipsychotic therapy and shortterm serious events in older adults with dementia. Arch Intern Med 2008;168(10):1090–1096.PubMedCrossRefGoogle Scholar
  34. 34.
    Zuidema SU, van Iersel MB, Koopmans RTCM, Verhey FRJ, Olde Rikkert MGM. Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review. Ned Tijdschr Geneesk 2006;150:1565-1573.Google Scholar
  35. 35.
    Allen MH. Managing the agitated psychotic patient: a reappraisal of evidence. J Clin Psychiatry1 2000;61:Suppl 14:11–20.Google Scholar
  36. 36.
    Battaglia J. Pharmacological management of acute agitation. Drugs 2005;65(9):1207–1222.PubMedCrossRefGoogle Scholar
  37. 37.
    Alexander J, Tharyan P, Adams C, John T, Mol C, Philip J. Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Br J Psychiatry 2004;185:63–69.PubMedCrossRefGoogle Scholar
  38. 38.
    Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Database of Systematic Reviews 2006, Issue 1.Google Scholar
  39. 39.
    Hanagasi HA, Emre M. Treatment of behavioural symptoms and dementia in Parkinson’s disease. Fundamentals & Clinical Pharmacology 2005;19(2):33–146.Google Scholar
  40. 40.
    Cahn W, et al. (2008) Preventie en behandeling van somatische complicaties bij antipsychoticagebruik. T v Psychiatrie 50(9):579–591.Google Scholar
  41. 41.
    Devanand DP. et al. Relapse risk after discontinuation of risperidon in Alzheimer’s disease. NEJM 2012;367:1497–1507.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Seitz DP, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews 2011, Issue 2.Google Scholar
  43. 43.
    Vieweg WV, et al. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med 2012;125(9):859–868.PubMedCrossRefGoogle Scholar
  44. 44.
    Lanctot KL, et al. Central serotonergic activity is related to aggressive behaviors of Alzheimer’s disease. Neuropsychopharmacology 2002;27:646–654.PubMedGoogle Scholar
  45. 45.
    Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006;66:17–22.PubMedCrossRefGoogle Scholar
  46. 46.
    Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson’s disease: on movement, mood, and madness. Movement Disorders 2009;24(9):1255–1266.PubMedCrossRefGoogle Scholar
  47. 47.
    Sultzer DL, et al. A double blind comparison of trazodon and haloperidol for the treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997;7:60–69.Google Scholar
  48. 48.
    Rolanski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy Bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. The Cochrane Library. 2012Google Scholar
  49. 49.
    Wattmo C, Wallin AK, Londos E, Minthon L. Risk factors for nursing home placement in Alzheimer’s disease: a longitudinal study of cognition, ADL, service utilization and cholinesterase inhibitor treatment. The Gerontologist 2010;51:17–27.PubMedCrossRefGoogle Scholar
  50. 50.
    Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, et al. (2012) Efficacy of Memantine for Agitation in Alzheimer’s Dementia: A Randomised Double-Blind Placebo Controlled Trial. PLoS ONE 7(5): e35185.CrossRefGoogle Scholar
  51. 51.
    Gauthier S, Loft H, Cummings J. Improvement of behavioural symptoms in patients with moderate tot severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry 2008;23(5):537–545.PubMedCrossRefGoogle Scholar
  52. 52.
    Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease. A pooled analysis of 3 studies. J Clin Psychiatry 2008;69:341–348.PubMedCrossRefGoogle Scholar
  53. 53.
    Wilkinson D. A review of the effects of memantine on clinical progression in Alzheimer’s disease. Int J Geriatr Psychiat 2011;27(8):769–76.CrossRefGoogle Scholar
  54. 54.
    Emre M, Tsolaki M, Bonuccelli U, Destée A, Tolosa E, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9(10):969–977.PubMedCrossRefGoogle Scholar
  55. 55.
    Swanberg MM. Memantine for behavioural disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord 2007;21(2):164–166.PubMedCrossRefGoogle Scholar
  56. 56.
    Boxer AL, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013;12(2):149–156.PubMedCentralPubMedCrossRefGoogle Scholar
  57. 57.
    Tamblyn R, Abrahamowicz M, Berger R du, McLeod P, Bartlett G. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 2005;53(2):233–241.PubMedCrossRefGoogle Scholar

Copyright information

© Bohn Stafleu van Loghum 2013

Authors and Affiliations

  • Dr. Peter van Domburg
    • 1
  • Marion Vromen
    • 1
  • Janine Collet
    • 2
  • Monique Durlinger
    • 3
  • Serge Roufs
    • 4
  • Jos Schols
    • 5
  • Walther Sipers
    • 1
  • Mike Verkaaik
    • 6
  • Frans Verhey
    • 6
  1. 1.Orbis GGZGeleen-SittardThe Netherlands
  2. 2.Mondriaan, Divisie OuderenHeerlenThe Netherlands
  3. 3.Vivre, Locatie KlevarieMaastrichtThe Netherlands
  4. 4.GGzE, Centrum OuderenpsychiatrieEindhovenThe Netherlands
  5. 5.Dept. of General Practice and Dept. Health Services ResearchCaphri – School for Public Health and Primary CareMaastrichtThe Netherlands
  6. 6.MUMCMaastrichtThe Netherlands

Personalised recommendations